Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by:
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT00005634
First received: May 2, 2000
Last updated: June 18, 2013
Last verified: June 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2002
  Primary Completion Date: October 2002 (Final data collection date for primary outcome measure)